← All stories
Markets
Akeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
Covered by 1 outlet
All coverage · 1 article